Novo Nordisk And Oxford University Announce Rheumatoid Arthritis Partnership

A new collaboration between Novo Nordisk and the Kennedy Institute of Rheumatology could pave the way for new drug candidates, biomarkers and treatment targets for autoimmune inflammatory diseases.

Novo Nordisk and Oxford University's Kennedy Institute of Rheumatology have announced a new partnership to develop drug candidates for autoimmune inflammatory diseases such as rheumatoid arthritis.

The collaboration will also seek to identify new biomarkers and treatment targets for these diseases, with Novo Nordisk funding ten researchers to work within the partnership at the Kennedy Institute.

Scientists at the institute have already made important breakthroughs in the field, with head Professor Sir Marc Feldmann and colleague Sir Ravinder Maini previously discovering the potential of anti-tumour necrosis factor (anti-TNF) therapies.

Professor Feldmann said: "We will work closely together wit